Loading...
XTSE
HBP
Market cap78mUSD
, Last price  
CAD
Name

Helix Biopharma Corp

Chart & Performance

D1W1MN
XTSE:HBP chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.89%
Rev. gr., 5y
%
Revenues
0k
3,424,0003,591,0003,841,0004,434,0004,532,0004,260,0000000000000000
Net income
-5m
L-43.81%
-7,674,000-6,964,000-14,102,000-14,469,000-11,348,000-17,440,000-1,570,000-8,701,000-8,743,000-9,682,000-10,073,000-8,654,000-7,527,000-9,010,000-7,911,000-6,080,000-6,290,000-9,264,000-5,205,000
CFO
-4m
L-26.60%
-6,079,000-6,997,000-13,157,000-12,193,000-10,339,000-14,112,000-7,814,000-7,692,000-8,488,000-8,853,000-9,295,000-7,524,000-5,531,000-10,826,000-9,304,000-6,509,000-5,527,000-5,219,000-3,831,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has formed strategic alliances, including one with Moffitt Cancer Center to analyze L-DOS47's pharmacodynamics and assess the benefits of integrating it with immune checkpoint inhibitors. Another partnership, with ProMab Biotechnologies, Inc., is dedicated to creating innovative antibody and chimeric antigen receptor T-cell therapies to combat multiple myeloma. Furthermore, the company maintains licensing agreements with Xisle Pharma Ventures Trust and the National Research Council Canada.
URL
https://www.helixbiopharma.com/
IPO date
Jun 03, 1996
Employees
7
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑072024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑07
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT